TY  - JOUR
AU  - Radojević-Škodrić, Sanja
AU  - Brašanac, Dimitrije
AU  - Đuričić, Slaviša M.
AU  - Glumac, Sofija
AU  - Lončar, Zlatibor
AU  - Pavlović, Ivan
AU  - Todorović, Ana
AU  - Nikolić, Gorana V.
AU  - Baralić, Ivana
AU  - Pejić, Snežana
PY  - 2019
UR  - https://peerj.com/articles/6212
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8025
AB  - Background: Cyclin A overexpression is found in a variety of human tumors and correlates with unfavorable outcome. We analyzed immunohistochemical expression of cyclin A in Wilms tumor (WT) in relation to clinicopathological characteristics, preoperative chemotherapy (PrOpChTh), and overall survival (OS). Methods: This retrospective study involved 43 patients who underwent nephrectomy from January 1996 to October 2010. Tumor stage and histological subtype were determined by revised Societé International d’Oncologie Pediatrique protocol, based on histological components/alterations caused by PrOpChTh, within the prognostic group of low, intermediate and high risk, and with criteria for anaplasia. The regressive/necrotic changes in total tumor mass of primary tumor and the proportion of epithelial, blastemal, and stromal components in the remaining viable tumor tissue were also determined. Cyclin A expression was evaluated by immunohistochemistry using a polyclonal rabbit, antihuman antibody (H-432). Results: Cyclin A overexpression was found in 34.3% of WTs, with higher frequency in tumors with epithelial (31.3%) and blastemal (37.1%) components than those with stromal component (17.7%). Regarding histological type, cyclin A overexpression was found most often in focal anaplasia (100%), stromal (60%), and diffuse anaplastic (66.7) WTs. The overexpression was also more frequent in stages 3 and 4 (77.8% and 66.7%, respectively) compared to tumors in stages 1 and 2 (13.3% and 12.5%, respectively; p = 0.004) in all components, as well as in blastemal component in stages 3 and 4 (77.8% and 66.7%, respectively) vs. stages 1 and 2 (13.3% and 25%, respectively, p = 0.009). Cyclin A overexpression in all components was 66.7% in WTs with metastasis and 31.3% in WTs without metastasis (p = 0.265, Fisher test). Log-rank testing revealed differences of OS regarding stage (p = 0.000), prognostic groups (p = 0.001), and cyclin A expression in blastemal component (p = 0.025). After univariate analysis, tumor stage (p = 0.001), prognostic group (p = 0.004), and cyclin A expression in blastemal component (p = 0.042) were significant prognostic factors for OS; however, after multivariate analysis, none of these factors were confirmed as independent predictors of survival. Discussion: This study showed that cyclin A overexpression might be associated with the development and progression of WT with anaplasia. Also, cyclin A overexpression was more often observed in advanced stages (3 and 4) of WT, in the group of high-risk WTs, and in focal and diffuse anaplasia WTs. There was no relation of cyclin A overexpression and metastatic ability of WT. Although this study has not confirmed the prognostic value of cyclin A overexpression, its association with unfavorable prognosis should be further evaluated. Copyright 2019 Radojevic-Škodric et al.
T2  - PeerJ
T1  - Immunohistochemical analysis of cyclin A expression in Wilms tumor
VL  - 6
IS  - 1
SP  - e6212
DO  - 10.7717/peerj.6212
ER  - 

@article{
author = "Radojević-Škodrić, Sanja and Brašanac, Dimitrije and Đuričić, Slaviša M. and Glumac, Sofija and Lončar, Zlatibor and Pavlović, Ivan and Todorović, Ana and Nikolić, Gorana V. and Baralić, Ivana and Pejić, Snežana",
year = "2019",
abstract = "Background: Cyclin A overexpression is found in a variety of human tumors and correlates with unfavorable outcome. We analyzed immunohistochemical expression of cyclin A in Wilms tumor (WT) in relation to clinicopathological characteristics, preoperative chemotherapy (PrOpChTh), and overall survival (OS). Methods: This retrospective study involved 43 patients who underwent nephrectomy from January 1996 to October 2010. Tumor stage and histological subtype were determined by revised Societé International d’Oncologie Pediatrique protocol, based on histological components/alterations caused by PrOpChTh, within the prognostic group of low, intermediate and high risk, and with criteria for anaplasia. The regressive/necrotic changes in total tumor mass of primary tumor and the proportion of epithelial, blastemal, and stromal components in the remaining viable tumor tissue were also determined. Cyclin A expression was evaluated by immunohistochemistry using a polyclonal rabbit, antihuman antibody (H-432). Results: Cyclin A overexpression was found in 34.3% of WTs, with higher frequency in tumors with epithelial (31.3%) and blastemal (37.1%) components than those with stromal component (17.7%). Regarding histological type, cyclin A overexpression was found most often in focal anaplasia (100%), stromal (60%), and diffuse anaplastic (66.7) WTs. The overexpression was also more frequent in stages 3 and 4 (77.8% and 66.7%, respectively) compared to tumors in stages 1 and 2 (13.3% and 12.5%, respectively; p = 0.004) in all components, as well as in blastemal component in stages 3 and 4 (77.8% and 66.7%, respectively) vs. stages 1 and 2 (13.3% and 25%, respectively, p = 0.009). Cyclin A overexpression in all components was 66.7% in WTs with metastasis and 31.3% in WTs without metastasis (p = 0.265, Fisher test). Log-rank testing revealed differences of OS regarding stage (p = 0.000), prognostic groups (p = 0.001), and cyclin A expression in blastemal component (p = 0.025). After univariate analysis, tumor stage (p = 0.001), prognostic group (p = 0.004), and cyclin A expression in blastemal component (p = 0.042) were significant prognostic factors for OS; however, after multivariate analysis, none of these factors were confirmed as independent predictors of survival. Discussion: This study showed that cyclin A overexpression might be associated with the development and progression of WT with anaplasia. Also, cyclin A overexpression was more often observed in advanced stages (3 and 4) of WT, in the group of high-risk WTs, and in focal and diffuse anaplasia WTs. There was no relation of cyclin A overexpression and metastatic ability of WT. Although this study has not confirmed the prognostic value of cyclin A overexpression, its association with unfavorable prognosis should be further evaluated. Copyright 2019 Radojevic-Škodric et al.",
journal = "PeerJ",
title = "Immunohistochemical analysis of cyclin A expression in Wilms tumor",
volume = "6",
number = "1",
pages = "e6212",
doi = "10.7717/peerj.6212"
}

Radojević-Škodrić, S., Brašanac, D., Đuričić, S. M., Glumac, S., Lončar, Z., Pavlović, I., Todorović, A., Nikolić, G. V., Baralić, I.,& Pejić, S.. (2019). Immunohistochemical analysis of cyclin A expression in Wilms tumor. in PeerJ, 6(1), e6212.
https://doi.org/10.7717/peerj.6212

Radojević-Škodrić S, Brašanac D, Đuričić SM, Glumac S, Lončar Z, Pavlović I, Todorović A, Nikolić GV, Baralić I, Pejić S. Immunohistochemical analysis of cyclin A expression in Wilms tumor. in PeerJ. 2019;6(1):e6212.
doi:10.7717/peerj.6212 .

Radojević-Škodrić, Sanja, Brašanac, Dimitrije, Đuričić, Slaviša M., Glumac, Sofija, Lončar, Zlatibor, Pavlović, Ivan, Todorović, Ana, Nikolić, Gorana V., Baralić, Ivana, Pejić, Snežana, "Immunohistochemical analysis of cyclin A expression in Wilms tumor" in PeerJ, 6, no. 1 (2019):e6212,
https://doi.org/10.7717/peerj.6212 . .

TY  - JOUR
AU  - Latić, Dragana
AU  - Pejić, Snežana
AU  - Savić, Slaviša
AU  - Lončar, Zlatibor
AU  - Nikolić, Ivan M.
AU  - Nikolić, Gorana V.
AU  - Pavlović, Ivan
AU  - Radojević-Škodrić, Sanja
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8078
AB  - Purpose: There is a need for identifying molecular prognostic biomarkers to better predict clinical outcomes in patients with renal cell carcinoma (RCC). This study investigated the pattern of cyclin D1 and p57 expression in RCC patients and evaluated their relation with clinicopathological characteristics and overall survival (OS). Methods: Immunohistochemistry was applied to paraffin-embedded tissue sections of 74 RCC patients. Two cut-off groups were defined by the fraction of positive cells as fol-lows: ≤10% and >10% positive cells for cyclin D1, and ≤5% and >5% positive cells for p57. Results: Cyclin D1 expression in >10% of positive cells was observed mostly in the clear cell RCC, while p57 expression in ≤5% of positive cells was found in 86% of chromophobe RCC specimens. The higher expression of cyclin D1 and lower expression of p57 were more frequent in grade I-II tumors. OS was associated with unfavorable clinicopathological characteristics. However, cyclin D1/p57 expression did not influence the survival rates. Conclusion: Although cyclin D1 and p57 expression did not affect survival rates in RCC patients, proper validation and establishment of the qualitative cut-off point are needed for these tumors.
T2  - Journal of BUON
T1  - Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma
VL  - 24
IS  - 1
SP  - 301
EP  - 309
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8078
ER  - 

@article{
author = "Latić, Dragana and Pejić, Snežana and Savić, Slaviša and Lončar, Zlatibor and Nikolić, Ivan M. and Nikolić, Gorana V. and Pavlović, Ivan and Radojević-Škodrić, Sanja",
year = "2019",
abstract = "Purpose: There is a need for identifying molecular prognostic biomarkers to better predict clinical outcomes in patients with renal cell carcinoma (RCC). This study investigated the pattern of cyclin D1 and p57 expression in RCC patients and evaluated their relation with clinicopathological characteristics and overall survival (OS). Methods: Immunohistochemistry was applied to paraffin-embedded tissue sections of 74 RCC patients. Two cut-off groups were defined by the fraction of positive cells as fol-lows: ≤10% and >10% positive cells for cyclin D1, and ≤5% and >5% positive cells for p57. Results: Cyclin D1 expression in >10% of positive cells was observed mostly in the clear cell RCC, while p57 expression in ≤5% of positive cells was found in 86% of chromophobe RCC specimens. The higher expression of cyclin D1 and lower expression of p57 were more frequent in grade I-II tumors. OS was associated with unfavorable clinicopathological characteristics. However, cyclin D1/p57 expression did not influence the survival rates. Conclusion: Although cyclin D1 and p57 expression did not affect survival rates in RCC patients, proper validation and establishment of the qualitative cut-off point are needed for these tumors.",
journal = "Journal of BUON",
title = "Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma",
volume = "24",
number = "1",
pages = "301-309",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8078"
}

Latić, D., Pejić, S., Savić, S., Lončar, Z., Nikolić, I. M., Nikolić, G. V., Pavlović, I.,& Radojević-Škodrić, S.. (2019). Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma. in Journal of BUON, 24(1), 301-309.
https://hdl.handle.net/21.15107/rcub_vinar_8078

Latić D, Pejić S, Savić S, Lončar Z, Nikolić IM, Nikolić GV, Pavlović I, Radojević-Škodrić S. Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma. in Journal of BUON. 2019;24(1):301-309.
https://hdl.handle.net/21.15107/rcub_vinar_8078 .

Latić, Dragana, Pejić, Snežana, Savić, Slaviša, Lončar, Zlatibor, Nikolić, Ivan M., Nikolić, Gorana V., Pavlović, Ivan, Radojević-Škodrić, Sanja, "Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma" in Journal of BUON, 24, no. 1 (2019):301-309,
https://hdl.handle.net/21.15107/rcub_vinar_8078 .